Free Trial
→ Elon Musk’s $1 Quadrillion AI IPO (From Brownstone Research) (Ad)tc pixel Free BSX Stock Alerts

Boston Scientific (BSX) Competitors

Boston Scientific logo
$48.32 -0.79 (-1.61%)
Closing price 05/29/2026 03:59 PM Eastern
Extended Trading
$48.39 +0.07 (+0.14%)
As of 05/29/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

BSX vs. ALGN, HQY, MMSI, AMN, and CAH

Should you buy Boston Scientific stock or one of its competitors? MarketBeat compares Boston Scientific with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Boston Scientific include Align Technology (ALGN), HealthEquity (HQY), Merit Medical Systems (MMSI), AMN Healthcare Services (AMN), and Cardinal Health (CAH). These companies are all part of the "medical" sector.

How does Boston Scientific compare to Align Technology?

Boston Scientific (NYSE:BSX) and Align Technology (NASDAQ:ALGN) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

Boston Scientific has a net margin of 17.29% compared to Align Technology's net margin of 10.50%. Boston Scientific's return on equity of 19.17% beat Align Technology's return on equity.

Company Net Margins Return on Equity Return on Assets
Boston Scientific17.29% 19.17% 10.77%
Align Technology 10.50%15.82%10.17%

Boston Scientific has higher revenue and earnings than Align Technology. Boston Scientific is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Boston Scientific$20.07B3.58$2.90B$2.3920.22
Align Technology$4.03B3.11$410.35M$5.9629.35

In the previous week, Boston Scientific had 48 more articles in the media than Align Technology. MarketBeat recorded 56 mentions for Boston Scientific and 8 mentions for Align Technology. Boston Scientific's average media sentiment score of 0.63 beat Align Technology's score of 0.51 indicating that Boston Scientific is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Boston Scientific
28 Very Positive mention(s)
8 Positive mention(s)
9 Neutral mention(s)
5 Negative mention(s)
4 Very Negative mention(s)
Positive
Align Technology
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Boston Scientific has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Align Technology has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market.

89.1% of Boston Scientific shares are owned by institutional investors. Comparatively, 88.4% of Align Technology shares are owned by institutional investors. 0.3% of Boston Scientific shares are owned by company insiders. Comparatively, 0.8% of Align Technology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Boston Scientific currently has a consensus target price of $87.46, suggesting a potential upside of 81.00%. Align Technology has a consensus target price of $205.85, suggesting a potential upside of 17.66%. Given Boston Scientific's stronger consensus rating and higher possible upside, analysts clearly believe Boston Scientific is more favorable than Align Technology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Boston Scientific
0 Sell rating(s)
5 Hold rating(s)
22 Buy rating(s)
1 Strong Buy rating(s)
2.86
Align Technology
0 Sell rating(s)
6 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.57

Summary

Boston Scientific beats Align Technology on 13 of the 17 factors compared between the two stocks.

How does Boston Scientific compare to HealthEquity?

HealthEquity (NASDAQ:HQY) and Boston Scientific (NYSE:BSX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Boston Scientific has a net margin of 17.29% compared to HealthEquity's net margin of 17.25%. Boston Scientific's return on equity of 19.17% beat HealthEquity's return on equity.

Company Net Margins Return on Equity Return on Assets
HealthEquity17.25% 14.75% 9.22%
Boston Scientific 17.29%19.17%10.77%

Boston Scientific has higher revenue and earnings than HealthEquity. Boston Scientific is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HealthEquity$1.31B5.60$215.20M$2.6732.96
Boston Scientific$20.07B3.58$2.90B$2.3920.22

HealthEquity has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market. Comparatively, Boston Scientific has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

HealthEquity presently has a consensus price target of $112.36, indicating a potential upside of 27.69%. Boston Scientific has a consensus price target of $87.46, indicating a potential upside of 81.00%. Given Boston Scientific's higher possible upside, analysts plainly believe Boston Scientific is more favorable than HealthEquity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HealthEquity
1 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.87
Boston Scientific
0 Sell rating(s)
5 Hold rating(s)
22 Buy rating(s)
1 Strong Buy rating(s)
2.86

99.6% of HealthEquity shares are owned by institutional investors. Comparatively, 89.1% of Boston Scientific shares are owned by institutional investors. 1.6% of HealthEquity shares are owned by insiders. Comparatively, 0.3% of Boston Scientific shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Boston Scientific had 39 more articles in the media than HealthEquity. MarketBeat recorded 56 mentions for Boston Scientific and 17 mentions for HealthEquity. HealthEquity's average media sentiment score of 0.74 beat Boston Scientific's score of 0.63 indicating that HealthEquity is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
HealthEquity
4 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Boston Scientific
28 Very Positive mention(s)
8 Positive mention(s)
9 Neutral mention(s)
5 Negative mention(s)
4 Very Negative mention(s)
Positive

Summary

Boston Scientific beats HealthEquity on 9 of the 16 factors compared between the two stocks.

How does Boston Scientific compare to Merit Medical Systems?

Merit Medical Systems (NASDAQ:MMSI) and Boston Scientific (NYSE:BSX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

99.7% of Merit Medical Systems shares are held by institutional investors. Comparatively, 89.1% of Boston Scientific shares are held by institutional investors. 0.7% of Merit Medical Systems shares are held by company insiders. Comparatively, 0.3% of Boston Scientific shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Boston Scientific has a net margin of 17.29% compared to Merit Medical Systems' net margin of 9.03%. Boston Scientific's return on equity of 19.17% beat Merit Medical Systems' return on equity.

Company Net Margins Return on Equity Return on Assets
Merit Medical Systems9.03% 13.54% 7.94%
Boston Scientific 17.29%19.17%10.77%

Merit Medical Systems has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Boston Scientific has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

Boston Scientific has higher revenue and earnings than Merit Medical Systems. Boston Scientific is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merit Medical Systems$1.52B2.48$128.49M$2.3127.31
Boston Scientific$20.07B3.58$2.90B$2.3920.22

In the previous week, Boston Scientific had 42 more articles in the media than Merit Medical Systems. MarketBeat recorded 56 mentions for Boston Scientific and 14 mentions for Merit Medical Systems. Merit Medical Systems' average media sentiment score of 0.80 beat Boston Scientific's score of 0.63 indicating that Merit Medical Systems is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Merit Medical Systems
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Boston Scientific
28 Very Positive mention(s)
8 Positive mention(s)
9 Neutral mention(s)
5 Negative mention(s)
4 Very Negative mention(s)
Positive

Merit Medical Systems currently has a consensus price target of $92.80, indicating a potential upside of 47.09%. Boston Scientific has a consensus price target of $87.46, indicating a potential upside of 81.00%. Given Boston Scientific's stronger consensus rating and higher possible upside, analysts plainly believe Boston Scientific is more favorable than Merit Medical Systems.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Merit Medical Systems
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.64
Boston Scientific
0 Sell rating(s)
5 Hold rating(s)
22 Buy rating(s)
1 Strong Buy rating(s)
2.86

Summary

Boston Scientific beats Merit Medical Systems on 13 of the 17 factors compared between the two stocks.

How does Boston Scientific compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and Boston Scientific (NYSE:BSX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

Boston Scientific has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AMN Healthcare Services$2.73B0.41-$95.70M-$0.87N/A
Boston Scientific$20.07B3.58$2.90B$2.3920.22

AMN Healthcare Services has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market. Comparatively, Boston Scientific has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

AMN Healthcare Services presently has a consensus price target of $25.29, suggesting a potential downside of 13.09%. Boston Scientific has a consensus price target of $87.46, suggesting a potential upside of 81.00%. Given Boston Scientific's stronger consensus rating and higher possible upside, analysts plainly believe Boston Scientific is more favorable than AMN Healthcare Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AMN Healthcare Services
2 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.22
Boston Scientific
0 Sell rating(s)
5 Hold rating(s)
22 Buy rating(s)
1 Strong Buy rating(s)
2.86

Boston Scientific has a net margin of 17.29% compared to AMN Healthcare Services' net margin of -0.95%. Boston Scientific's return on equity of 19.17% beat AMN Healthcare Services' return on equity.

Company Net Margins Return on Equity Return on Assets
AMN Healthcare Services-0.95% 18.01% 5.19%
Boston Scientific 17.29%19.17%10.77%

99.2% of AMN Healthcare Services shares are owned by institutional investors. Comparatively, 89.1% of Boston Scientific shares are owned by institutional investors. 1.1% of AMN Healthcare Services shares are owned by company insiders. Comparatively, 0.3% of Boston Scientific shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Boston Scientific had 45 more articles in the media than AMN Healthcare Services. MarketBeat recorded 56 mentions for Boston Scientific and 11 mentions for AMN Healthcare Services. Boston Scientific's average media sentiment score of 0.63 beat AMN Healthcare Services' score of 0.22 indicating that Boston Scientific is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AMN Healthcare Services
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Boston Scientific
28 Very Positive mention(s)
8 Positive mention(s)
9 Neutral mention(s)
5 Negative mention(s)
4 Very Negative mention(s)
Positive

Summary

Boston Scientific beats AMN Healthcare Services on 15 of the 17 factors compared between the two stocks.

How does Boston Scientific compare to Cardinal Health?

Cardinal Health (NYSE:CAH) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Cardinal Health has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, Boston Scientific has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

Cardinal Health presently has a consensus target price of $241.80, suggesting a potential upside of 23.01%. Boston Scientific has a consensus target price of $87.46, suggesting a potential upside of 81.00%. Given Boston Scientific's higher probable upside, analysts clearly believe Boston Scientific is more favorable than Cardinal Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardinal Health
0 Sell rating(s)
2 Hold rating(s)
15 Buy rating(s)
1 Strong Buy rating(s)
2.94
Boston Scientific
0 Sell rating(s)
5 Hold rating(s)
22 Buy rating(s)
1 Strong Buy rating(s)
2.86

87.2% of Cardinal Health shares are held by institutional investors. Comparatively, 89.1% of Boston Scientific shares are held by institutional investors. 0.1% of Cardinal Health shares are held by insiders. Comparatively, 0.3% of Boston Scientific shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Boston Scientific has a net margin of 17.29% compared to Cardinal Health's net margin of 0.62%. Boston Scientific's return on equity of 19.17% beat Cardinal Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Cardinal Health0.62% -92.61% 4.46%
Boston Scientific 17.29%19.17%10.77%

In the previous week, Boston Scientific had 52 more articles in the media than Cardinal Health. MarketBeat recorded 56 mentions for Boston Scientific and 4 mentions for Cardinal Health. Cardinal Health's average media sentiment score of 0.89 beat Boston Scientific's score of 0.63 indicating that Cardinal Health is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cardinal Health
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Boston Scientific
28 Very Positive mention(s)
8 Positive mention(s)
9 Neutral mention(s)
5 Negative mention(s)
4 Very Negative mention(s)
Positive

Boston Scientific has lower revenue, but higher earnings than Cardinal Health. Boston Scientific is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardinal Health$222.58B0.21$1.56B$6.5430.06
Boston Scientific$20.07B3.58$2.90B$2.3920.22

Summary

Boston Scientific beats Cardinal Health on 11 of the 16 factors compared between the two stocks.

Get Boston Scientific News Delivered to You Automatically

Sign up to receive the latest news and ratings for BSX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BSX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BSX vs. The Competition

Export
MetricBoston ScientificMED PRODUCTS IndustryMedical SectorNYSE Exchange
Market Cap$71.81B$8.29B$6.58B$23.19B
Dividend YieldN/A2.54%2.68%4.09%
P/E Ratio20.2215.8521.5930.62
Price / Sales3.588.37561.7724.75
Price / Cash11.9717.5727.4419.43
Price / Book2.933.6910.044.70
Net Income$2.90B$224.05M$3.56B$1.07B
7 Day Performance-16.28%3.72%2.85%1.14%
1 Month Performance-16.25%4.14%4.59%1.26%
1 Year Performance-54.02%3.90%37.62%28.06%

Boston Scientific Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BSX
Boston Scientific
4.867 of 5 stars		$48.32
-1.6%		$87.46
+81.0%		-54.0%$71.81B$20.07B20.2259,000
ALGN
Align Technology
2.8348 of 5 stars		$163.61
flat		$205.85
+25.8%		-3.2%$11.72B$4.03B27.4520,290
HQY
HealthEquity
4.2902 of 5 stars		$88.11
flat		$111.79
+26.9%		-13.0%$7.39B$1.31B35.822,814
MMSI
Merit Medical Systems
4.6842 of 5 stars		$64.17
flat		$92.80
+44.6%		-33.6%$3.83B$1.52B27.787,500
AMN
AMN Healthcare Services
1.6306 of 5 stars		$27.65
0.0%		$25.29
-8.6%		+38.0%$1.07B$3.42BN/A2,664

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:BSX) was last updated on 5/31/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel